Company intelligence / Profile preview

Orvida Pharma

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Orvida Pharma is a clinical-stage precision oncology company dedicated to developing next-generation therapies for patients with genetically defined cancers. The company was established by the founding leadership team of Turning Point Therapeutics to advance ORV-101 (formerly TPX-0131), a potent and selective ALK inhibitor acquired from Bristol Myers Squibb. Orvida focuses on overcoming clinical resistance mutations in non-small cell lung cancer that limit the effectiveness of existing treatments. By leveraging deep expertise in structure-based drug design, the company aims to deliver best-in-class targeted medicines to address significant unmet needs in oncology.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

lanavatrep

Unknown

Partnerships

Bristol Myers Squibb

Beyond the preview

Go deeper on Orvida Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orvida Pharma.

Explore the full profile